In line with a previous report where only engineered tumor progression organoids with increasing number of cancer mutations (APC, KRAS, P53 and/or SMAD4) showed efficient engraftment (Drost et al., 2015), we only obtained reliable engraftment using P26T CRC organoids. The gene discussed is TP53; the disease is neoplasm.